The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have proposed the continuation of the Drug-Induced Liver Injury Network (DILIN). As described in the RFA, DILIN will be a network composed of up to 5 Clinical Centers (CCs) with expertise in diagnosis and management of DILI and a Data Coordinating Center (DCC) with expertise in the management of multicenter studies and clinical and translational datasets. The purpose of this research program is to enhance the enrollment of cases and controls (when justified) from a diverse demographic and wide geographic distribution. The major aim of the network study is to pursue pharmacogenetic analyses to find predictive biomarkers as well as genetic """"""""fingerprints"""""""" useful for elucidating the pathogenesis of Drug-Induced Liver Injury (DILI) and ultimately for developing specific means of prevention and or treatment. The Duke Clinical Research Institute (DCRI) proposes to continue as the DCC for DILIN. In this role, we will apply our extensive experience and research infrastructure to coordinate, support and facilitate the activities of the DILIN network. In particular, we will atted to the following specific aims: (1) Explore and Determine the use of LiverTox case report for enrollment from a wide demographic and geographic distribution throughout US;(2) Support protocol development of pharmacogenetic and biomarker studies and studies with intervention strategies to prevent and treat DILI;(3) Support development of a validated, computer-based instrument and diagnosis of DILI which is accurate, simple and practical for clinicians;(4) Support manuscript preparation;(5) Provide overall network Coordination and Logistics;(6) Ensure quality assurance and continue data management activities;(7) Contribute to maintain LiverTox;(8) Provide statistical leadership in design and analysis Issues;(9) Support ancillary studies.

Public Health Relevance

Liver injury due to medication or herbal and dietary supplement use is an important medical, scientific, and public health problem in the US. Drug-induced liver injury (DILI) is the most common reason for non-approval, withdrawal, and clinical monitoring by the FDA. Understanding the dynamics of this medical problem and determining its clinical and genetic determinants will ultimately allow safer medications to be prescribed to patient populations and safer supplement on the market.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK065176-11S1
Application #
8729098
Study Section
Special Emphasis Panel (ZDK1-GRB-N (M7))
Program Officer
Serrano, Jose
Project Start
2003-09-30
Project End
2018-06-30
Budget Start
2013-09-11
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$337,253
Indirect Cost
$14,250
Name
Duke University
Department
Biostatistics & Other Math Sci
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Ahmad, Jawad; Odin, Joseph A; Hayashi, Paul H et al. (2017) Identification and Characterization of Fenofibrate-Induced Liver Injury. Dig Dis Sci 62:3596-3604
de Boer, Ynto S; Kosinski, Andrzej S; Urban, Thomas J et al. (2017) Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol 15:103-112.e2
Chalasani, Naga; Reddy, K Rajender K; Fontana, Robert J et al. (2017) Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. Am J Gastroenterol 112:1382-1388
Bonkovsky, Herbert L; Kleiner, David E; Gu, Jiezhun et al. (2017) Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology 65:1267-1277
Suzuki, Ayako; Barnhart, Huiman; Gu, Jiezhun et al. (2017) Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int 37:1723-1730
Nicoletti, Paola; Aithal, Guruprasad P; Bjornsson, Einar S et al. (2017) Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology 152:1078-1089
Hayashi, Paul H; Rockey, Don C; Fontana, Robert J et al. (2017) Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology 66:1275-1285
Urban, Thomas Jacob; Nicoletti, Paola; Chalasani, Naga et al. (2017) Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B?35:02 as a risk factor. J Hepatol 67:137-144
Navarro, Victor J; Khan, Ikhlas; Björnsson, Einar et al. (2017) Liver injury from herbal and dietary supplements. Hepatology 65:363-373
Whritenour, Jessica; Ko, Mira; Zong, Qing et al. (2017) Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol 14:31-38

Showing the most recent 10 out of 54 publications